Patent Issued

Kibow Biotech, Philadelphia, PA, has secured its first two U.S. patents for its scientifically validated, gut-based, uremia therapy products. Kibow is developing a probiotic and a pharmaceutical to reduce the buildup of uremic toxins in kidney disease patients. The two patents issued are U.S. No. 6,706,263 B2, titled, “Compositions for alleviating symptoms of uremia in patients” and U.S. Patent No. 6,706,287 B2, titled, “Prebiotic and Probiotic compositions and methods for their use in gut-based therapies.”